DVAX - ダイナバックス・テクノロジ―ズ (Dynavax Technologies Corporation) ダイナバックス・テクノロジ―ズ

 DVAXのチャート


 DVAXの企業情報

symbol DVAx
会社名 Dynavax Technologies Corp (ダイナバックス・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ダイナバクス・テクノロジーズ(Dynavax Technologies Corporation)は臨床段階の免疫療法会社である。同社はトール様受容体(TLR)刺激を通じて身体の本能と適応免疫応答を活用することに集中する。同社の製品候補は複数の癌適応症、B型肝炎の予防ワクチン、および喘息疾患修正療法として開発される。同社の製品はHEPLISAV-B、AZD1419、SD-101、DV281、DV230FとDV1001を含む。HEPLISAV-Bは治験成人のB型肝炎ワクチンである。AZD1419は喘息の治療として開発される。SD-101は癌に対する免疫応答を誘発するように設計される治験用TLR9アゴニストである。DV281は原発性肺腫瘍および肺転移への集中送達のためのTLR9アゴニストである。DV230Fは肝腫瘍の治療に適応する。DV1001は複数悪性腫瘍のTLR7、8アゴニストを標的とする。DV230FとDV1001は開発の前臨床段階である。   ダイナバックス・テクノロジ―ズは米国の臨床検査段階のバイオ医薬品会社。感染症、炎症性疾、自己免疫疾患治療薬の研究、開発に従事。候補製剤にはB型肝炎ワクチン「ヘプリサブ」、自己免疫疾患治療用「DV1179」、喘息治療用「AZD1419」、癌免疫療法「SD-101」などがある。   Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
本社所在地 2929 Seventh Street Suite 100 Berkeley CA 94710-2753 USA
代表者氏名 Arnold L. Oronsky アーノルドエルオロスキー
代表者役職名 Independent Chairman of the Board
電話番号 +1 510-848-5100
設立年月日 35278
市場名 NASDAQ Small Cap
ipoyear 2004年
従業員数 170人
url www.dynavax.com
nasdaq_url https://www.nasdaq.com/symbol/dvax
adr_tso
EBITDA EBITDA(百万ドル) -115.44000
終値(lastsale) 11.07
時価総額(marketcap) 693154537.02
時価総額 時価総額(百万ドル) 700.66840
売上高 売上高(百万ドル) 1.49300
企業価値(EV) 企業価値(EV)(百万ドル) 584.39640
当期純利益 当期純利益(百万ドル) -127.95100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Dynavax Technologies Corporation revenues increased from $253K to $1.4M. Net loss increased 72% to $78.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $2.3M to $17.5M (expense).

 DVAXのテクニカル分析


 DVAXのニュース

   Analysts’ Recommendations to Consider: Just Eat Takeaway.com N.V. (NASDAQ:GRUB), Dynavax Technologies Corporation (NASDAQ:DVAX)  2021/07/07 22:05:48 Stock Equity
Just Eat Takeaway.com N.V. (NASDAQ:GRUB) with the stream of 1.25% also noticed, India Dynavax Technologies Corporation (NASDAQ:DVAX) encountered a rapid change of -3.00% in the last hour of Wednesday’s trading … The post Analysts’ Recommendations to Consider: Just Eat Takeaway.com N.V. (NASDAQ:GRUB), Dynavax Technologies Corporation (NASDAQ:DVAX) appeared first on Stocks Equity .
   Biological E to use Dynavaxs adjuvant in Corbevax  2021/07/06 17:10:26 The Hindu
Biological E (BE) on Tuesday said it will use U.S. biopharmaceutical firm Dynavax Technologies Corporations CpG 1018 advanced adjuvant in its sub uni
   COVID-19: Dynavax to supply substance for Biological E''s COVID-19 vaccine candidate  2021/07/06 14:58:23 The Siasat Daily
Hyderabad: Biopharmaceutical company Dynavax Technologies Corporation and city-based vaccine and pharma company Biological E. Limited (BE), today
   Biological E To Buy Dynavax''s CpG 1018 Adjuvant For COVID-19 Vaccine Candidate  2021/07/06 12:24:50 Business Insider Markets
(RTTNews) - Biological E. Limited, a Hyderabad-based vaccine and pharmaceutical company, agreed to buy CpG 1018 adjuvant from Dynavax Technologies Corp. (DVAX) for use in the commercial production of Biological E''s COVID-19 vaccine candidate, CORBEVAX. The companies have extended their commercial supply agreement through 2022. The agreement
   Dynavax to supply its CpG 1018 adjuvant for Biological E''s COVID-19 Vaccine Candidate  2021/07/06 05:59:03 Devdiscourse
Dynavax Technologies Corporation a Nasdaq-listed firm, and Biological E.Limited (BE) on Tuesday announced the execution of a commercial supply agreement of the former''s CpG 1018 advanced adjuvant, for use in BEs subunit COVID-19 vaccine candidate, Corbevax.
   Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference  2021/06/09 00:00:00 BioSpace
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference.
   Emerging Trends in Cancer Vaccines Industry: Market Estimation 2021-2027 and Company Profiles: Advaxis Inc., Amgen Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, GlaxoSmithKline plc (GSK), Immunocellular Therapeutics, and more  2021/06/07 21:42:35 Jumbo News
AllTheResearchs Global Cancer Vaccines Market Strategic recommendations, Trends, Segmentation, Use case Analysis, Competitive Intelligence, Global and Regional Forecast (to 2026) report provides an overview of the market size of Cancer Vaccines for the regions United States, Europe (France, Germany, Italy, Spain, UK) and Japan, etc. Based on the Cancer Vaccines industrial chain, this report []
   Dynavax, Bavarian Nordic Ink Distribution Pact For Hepatitis B Vaccine In Germany  2021/05/27 12:47:38 Benzinga
Dynavax Technologies Corporation (NASDAQ: DVAX ) has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B, the Hepatitis B vaccine Full story available on Benzinga.com
   Bavarian Nordic A/S: Bavarian Nordic Announces Marketing and Distribution Agreement with Dynavax to Launch HEPLISAV B Hepatitis B Vaccine in Germany  2021/05/27 05:17:00 FinanzNachrichten
COPENHAGEN, Denmark, May 27 2021 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has entered a partnership with Dynavax Technologies Corporation (Nasdaq: DVAX) a biopharmaceutical company focused on
   Bavarian Nordic Announces Marketing and Distribution Agreement with Dynavax to Launch HEPLISAV B® Hepatitis B Vaccine in Germany  2021/05/27 05:15:00 GlobeNewswire
COPENHAGEN, Denmark, May 27 2021 Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has entered a partnership with Dynavax Technologies Corporation (Nasdaq: DVAX) a biopharmaceutical company focused on developing and commercializing novel vaccines for the marketing and distribution of their HEPLISAV B ® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Hepatitis B vaccine in Germany with an expected launch in the fourth quarter of 2021.
   Dynavax, Bavarian Nordic Ink Distribution Pact For Hepatitis B Vaccine In Germany  2021/05/27 12:47:38 Benzinga
Dynavax Technologies Corporation (NASDAQ: DVAX ) has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B, the Hepatitis B vaccine … Full story available on Benzinga.com
   Dynavax Technologies Corp. Shares Close the Week 20.5% Lower - Weekly Wrap  2021/05/14 22:30:00 Kwhen Finance
Dynavax Technologies Corp. (DVAX) shares closed this week 20.5% lower than it did at the end of last week. The stock is currently up 75.3% year-to-date, up 71.4% over the past 12 months, and down 48.8% over the past five years. This week, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.3%. Trading Activity Shares traded as high as $9.26 and as low as $7.09 this week.Shares closed 4e+1% below its 52-week high and 1e+2% above its 52-week low.Trading volume this week was 26.5% lower than the 10-day average and 15.0% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 6491.1% The company's stock price performance over the past 12 months beats the peer average by -10430.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Dynavax Technologies Corp. Shares Close the Day 10.5% Higher - Daily Wrap  2021/05/07 22:30:00 Kwhen Finance
Dynavax Technologies Corp. (DVAX) shares closed today 10.5% higher than it did at the end of yesterday. The stock is currently up 120.4% year-to-date, up 130.8% over the past 12 months, and down 30.4% over the past five years. Today, the Dow Jones Industrial Average rose 0.7%, and the S&P 500 rose 0.7%. Trading Activity Shares traded as high as $10.11 and as low as $8.48 this week.Shares closed 2e+1% below its 52-week high and 2e+2% above its 52-week low.Trading volume this week was 39.4% higher than the 10-day average and 29.1% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -23301.3% The company's stock price performance over the past 12 months beats the peer average by -5472.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ダイナバックス・テクノロジ―ズ DVAX Dynavax Technologies Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)